secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2023-04-13T23:59:59+00:00
Accession:  0001558370-23-005886
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine appoints Elliot Levy, M.D. as independent director
------------------------------------------------------------------

- Dr. Levy appointed as class I director; Board size increased by one member effective April 11, 2023.
- He will serve on the Audit Committee and Science and Technology Committee.
- Levy is a Venture Partner at 5AM Ventures; former SVP of R&D at Amgen; boards of Omega Therapeutics and NuCana.
- Annual cash compensation: $40,000 board + $7,500 Audit + $5,000 Science & Tech; option for 50,000 shares vesting over 3 years.
- No arrangement or understanding with any other person pursuant to which he was selected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023005886/0001558370-23-005886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023005886/edit-20230411x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-005886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer